Nasdaq:US$15.69 (+0.28) | HKEX:HK$25.40 (+0.50) | AIM:£2.21 (-0.02)
搜索
News & Press Releases
12345678910111213141516
17
1819
找到相關結果： 934
公告及新聞稿, 監管通知 | 2012-05-11

Results of Annual General Meeting
公告及新聞稿, 監管通知 | 2012-04-10

2011 Annual Report and Notice of Annual General Meeting
公告及新聞稿, 集團 | 2012-03-20

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook
公告及新聞稿, 腫瘤學 / 免疫學 | 2012-02-22

和黃醫藥啟動新型受體（c-Met）抑製劑沃利替尼（Volitinib ）Ⅰ期臨床試驗
2012 年2 月22 日：和黃醫藥今日宣佈在澳大利亞啟動沃利替尼（HMPL-504 ）I 期臨床試驗。沃利替尼是一種小分子新型靶向治療藥物，是c-Met 受體酪氨酸激酶的高選擇性抑製劑，用於癌症治
閱讀更多
查看公告 (PDF)
公告及新聞稿, 監管通知 | 2012-02-20

Notice of Announcement of 2011 Final Results
公告及新聞稿, 監管通知 | 2012-02-14

TR-1: Notification of major interests in shares
公告及新聞稿, 監管通知 | 2012-02-02

Total Voting Rights
公告及新聞稿, 監管通知 | 2012-01-05

TR-1: Notification of major interest in shares
公告及新聞稿, 監管通知 | 2011-12-29

Blocklisting Six Monthly Return
公告及新聞稿, 腫瘤學 / 免疫學 | 2011-12-21

阿斯利康與和黃醫藥強聯手 打造全球創新癌症治療方案
2011 年12 月21 日︰ 阿斯利康與和黃醫藥今日宣布，雙方簽署了一項合作協議，共同致力於沃利替尼( Volitinib , HMPL-504 ）在全球範圍內的開發、審批和銷售。和黃醫藥是一家領先的中國新藥
閱讀更多
查看公告 (PDF)
公告及新聞稿, 監管通知 | 2011-12-12

Chi-Med Loan Facility
公告及新聞稿, 腫瘤學 / 免疫學 | 2011-11-04

和黃醫藥啟動表皮生長因子受體（EGFR）抑製劑依吡替尼（Epitinib）Ⅰ期臨床試驗
2011 年11 月4 日：和黃醫藥今日宣布啟動依吡替尼（HMPL-813）Ⅰ期臨床試驗。依吡替尼是和黃醫藥研發項目中第三個進入國內臨床試驗的替代抗腫瘤抗體藥物。依吡替尼是作用於表皮生長因
閱讀更多
查看公告 (PDF)
公告及新聞稿, 監管通知 | 2011-09-05

TR-1: Notification of major interests in shares
公告及新聞稿, 集團 | 2011-08-01

Interim Results for the Six Months Ended 30 June 2011
公告及新聞稿, 其他業務 | 2011-07-22

China Healthcare Division expands OTC drug distribution and marketing operations
公告及新聞稿, 監管通知 | 2011-07-05

Notice of Announcement of 2011 Interim Results
公告及新聞稿, 監管通知 | 2011-06-29

Blocklisting Six Monthly Return
公告及新聞稿, 監管通知 | 2011-05-13

TR-1: Notification of major interests in shares
公告及新聞稿, 監管通知 | 2011-05-09

TR-1: Notification of major interests in shares
公告及新聞稿, 監管通知 | 2011-05-09

Results of Annual General Meeting
演示文稿, 科學出版物 | 2011-04-06

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models
公告及新聞稿, 監管通知 | 2011-04-04

2010 Annual Report and Notice of Annual General Meeting
公告及新聞稿, 監管通知 | 2011-03-28

Director's Shareholding
公告及新聞稿, 集團 | 2011-03-09

Final Results for the year ended 31 December 2010 Strong performance across all divisions.
公告及新聞稿, 監管通知 | 2011-02-21

Board Change
公告及新聞稿, 監管通知 | 2011-02-15

Appointment of UBS Limited as Joint Broker
公告及新聞稿, 腫瘤學 / 免疫學 | 2011-02-01

和黃醫藥獲SFDA批准啟動呋喹替尼一期臨床研究
星期二，2011 年2 月1 日：和黃醫藥今日宣佈在中國啟動1.1 類靶向抗癌新藥呋喹替尼一期臨床研究。同公司另一1.1 類靶向抗癌新藥索凡替尼一樣，呋喹替尼的新藥臨床研究申請是通過國家
閱讀更多
查看公告 (PDF)
公告及新聞稿, 監管通知 | 2011-01-31

Notice of Announcement of 2010 Final Results
公告及新聞稿, 監管通知 | 2011-01-05

Total Voting Rights
公告及新聞稿, 監管通知 | 2010-12-29

Blocklisting Six Monthly Return
公告及新聞稿, 腫瘤學 / 免疫學 | 2010-12-21

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline
公告及新聞稿, 其他業務 | 2010-12-10

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture
演示文稿, 科學出版物 | 2010-11-30

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)
公告及新聞稿, 腫瘤學 / 免疫學 | 2010-11-08

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline
演示文稿, 科學出版物 | 2010-10-16

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor
公告及新聞稿, 其他業務 | 2010-09-20

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China
公告及新聞稿, 監管通知 | 2010-09-15

Appointment of Joint Broker
公告及新聞稿, 集團 | 2010-07-29

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.
公告及新聞稿, 監管通知 | 2010-07-14

TR-1: Notification of major interests in shares
公告及新聞稿, 監管通知 | 2010-07-07

Notice of Announcement of 2010 Interim Results
公告及新聞稿, 監管通知 | 2010-07-07

TR-1: Notification of major interests in shares
公告及新聞稿, 監管通知 | 2010-07-05

Total Voting Rights
公告及新聞稿, 監管通知 | 2010-06-29

Blocklisting Six Monthly Return
公告及新聞稿, 監管通知 | 2010-06-25

Director's Shareholding
公告及新聞稿, 監管通知 | 2010-06-17

TR-1: Notification of major interests in shares
公告及新聞稿, 腫瘤學 / 免疫學 | 2010-04-30

和黃醫藥抗癌新藥索凡替尼獲得國家藥監局新藥臨床試驗批文
— 公司啟動索凡替尼一期臨床試驗 和黃醫藥宣布啟動其治療癌症的全新候選藥物索凡替尼的I 期臨床研究，第一例受試者於近日開始用藥。索凡替尼的新藥臨床試驗申請通過國家藥品食品
閱讀更多
查看公告 (PDF)
公告及新聞稿, 監管通知 | 2010-04-30

Results of Annual General Meeting
公告及新聞稿, 其他業務 | 2010-04-19

Seven-year extension of IP protection for Chi-Med's main prescription drug
公告及新聞稿, 監管通知 | 2010-03-29

2009 Annual Report and Notice of Annual General Meeting
公告及新聞稿, 監管通知 | 2010-03-15

TR-1: Notification of major interests in shares
12345678910111213141516
17
1819